QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: The LIFE study

European Heart Journal

Volumn 30, Issue 23, 2009, Pages 2908-2914

  Morin, Daniel P ^a   Oikarinen, Lasse ^b   Viitasalo, Matti ^b   Toivonen, Lauri ^b   Nieminen, Markku S ^b   Kjeldsen, Sverre E ^c   Dahlöf, Björn ^d   John, Majnu ^e   Devereux, Richard B ^e   Okin, Peter M ^e  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hypertension; Left ventricular hypertrophy; QRS duration; Sudden cardiac death

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART DEATH; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QRS COMPLEX; RISK ASSESSMENT; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE;

EID: 71549146315     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp321     Document Type: Article

References (44)

1. Podrid PJ, Myerberg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol 2005;28(Suppl. I):I3-I11.
2. Kreger BE, Cupples LA, Kannel WB. The electrocardiogram in prediction of sudden death: Framingham Study experience. Am Heart J 1987;113:377-382.
3. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-1459.
4. Mäkikallio TH, Barthel P, Schneider R, Bauer A, Tapanainen JM, Tulppo MP, Schmidt G, Huikuri HV. Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern era. Eur Heart J 2006;26: 762-769.
5. Huikuri HV, Castellanos A, Myerburg RJ. Sudden Death Due to Cardiac Arrhythmias. N Engl J Med 345 20:1473-1482.
6. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. QRS duration and mortality in patients with congestive heart failure. Am Heart J 2002;143:1085-1091.
7. Bode-Schnurbus L, Bocker D, Block M, Gradaus R, Heinecke A, Breithardt G, Borggrefe M. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart 2003;89:1157-1162.
8. Zimetbaum PJ, Buxton AE, Batsford W, Fisher JD, Hafley GE, Lee KL, O'Toole MF, Page RL, Reynolds M, Josephson ME. Electrocardiographic predictors of arrhythmic death and total mortality in the multicenter unsustained tachycardia trial. Circulation 2004;110:766-769.
9. Eriksson P, Wilhelmsen L, Rosengren A. Bundle-branch block in middle-aged men: risk of complications and death over 28 years. The primary prevention study in Göteborg, Sweden. Eur Heart J 2005;26:2300-2306.
10. Buxton AE, Sweeney MO, Wathen MS, Josephson ME, Otterness MF, Hogan-Miller E, Stark AJ, Degroot PJ. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverter- defibrillators. J Am Coll Cardiol 2005;46:310-316.
11. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, Devereux RB, Okin PM. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: The Losartan Intervention for Endpoint Reduction In Hypertension Study. Hypertension 2004;43:1029-1034. (Pubitemid 38579909)
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losar-tan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
13. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997;10:705-713.
14. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For End-point Reduction in Hypertension. Hypertension 1998;32:989-997.
15. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995;25:417-423.
16. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003;108: 684-690.
17. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B. Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy during antihyper-tensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349.
18. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992;20:1180-1186.
19. Sokolow M, Lyon TO. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and link leads. Am Heart J 1949;37:161-186.
20. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardio-graphic Findings: Standards and Procedures for Measurement and Classification. Boston, MA: John Wright; 1982.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
22. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007;116:700-705.
23. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V, Jern S, Dahlöf B, Devereux RB, Okin PM. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE Study. J Hypertens 2001;19: 1883-1891. (Pubitemid 32924957)
24. Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006;3:313-316.
25. Bauer A, Watanabe MA, Barthel P, Schneider R, Ulm K, Schmidt G. QRS duration and late mortality in unselected post-infarction patients of the revascularization era. Eur Heart J 2006;27:427-433.
26. Sakhuja R, Chen AA, Anwaruddin S, Baggish AL, Januzzi JL. Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. Am J Cardiol 2005;96:263-266.
27. Murkofsky RL, Dangas G, Diamond JA, Mehta D, Schaffer A, Ambrose JA. A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction. J Am Coll Cardiol 1998;32:476-482.
28. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA 2006;295:809-818.
29. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-2356.
30. Al-Khatib SM, Shaw LK, O'Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electro-physiol 2007;18:1231-1235.
31. Goldberger JJ, Kadish AH. Cardiac memory. PACE 1999;22:1672-1679.
32. Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006;47:269-281.
33. Ashwath ML, Okosun I, Sogade FO. QRS width and its impact on inducibility of ventricular arrhythmia at the time of electrophysiology study. J Natl Med Assoc 2005;97:695-698.
34. Berk BC, Fujiwara K, Lehoux S. ECM Remodeling in hypertensive heart disease. J Clin Invest 117:568-575.
35. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Reduced content of con-nexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993;88:864-875.
36. Kalahasti V, Manbi V, Martin DO, Lam CT, Yamada D, Wilkoff BL, Niebauer MJ, Jaeger FJ, Tchou PJ, Chung MK. QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. Am J Cardiol 2003;92:798-803.
37. Freedman RA, Alderman EL, Sheffield LT, Saporito M, Fisher LD. Bundle branch block in patients with chronic coronary artery disease: angiographic correlates and prognostic significance. J Am Coll Cardiol 1987;10:73-80.
38. Li Z, Devereux RB, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB. Association of left bundle branch block with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: The LIFE study. Am J Hypertens 2004;17:182A.
39. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-1940.
40. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890.
41. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
42. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implan-table cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
43. Myerberg RJ, Mitrani R, Interian A, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: Design features and population impact. Circulation 1998;97:1514-1521.
44. Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004;18:367-373.